Navigation Links
Celebrex-Lipitor combo may halt prostate cancer
Date:4/14/2008

e effects of the drugs on the growth of prostate cancer cells from four different cell lines. They then moved on to test the drugs on specially bred mice in which prostate cancer tumors were introduced under the skin. Celebrex alone, Lipitor alone, and the two in combination were tested at the lab bench and on the mice.

A combination of low doses of Lipitor and Celebrex had a more potent inhibiting effect on the formation of later stage tumors than a higher dose of either agent alone, Zheng reported. The results from our study indicate that a combination of Lipitor and Celebrex may be an effective strategy for the prevention of prostate cancer progression from the first to the second stage.

Zheng also noted that the team is exploring the underlying molecular mechanisms to understand how Lipitor and Celebrex work on prostate cancer, perhaps identifying an important signaling pathway for tumor cell growth that the drugs inhibit.

Conney pointed out that previous experiments reported in the Sept. 15, 2007, issue of Clinical Cancer Research had demonstrated that the Lipitor-Celebrex combination also inhibited the growth of prostate cancer cells in the later androgen-independent stage.

So if you can affect the early stage and prevent it from becoming the more severe form, thats a good thing. If you can also inhibit the growth of the more severe form, thats also a good thing, Conney said.

Human clinical trials are being planned at the Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey in New Brunswick.

If the clinical trials go well, we could have something available in five years, but it would be nice to speed that up, Conney said. If the trials show that the drug therapy does a good job of preventing the cancer from advancing, we wont need to worry about how to handle the more aggressive later stage cancer.

This is something we hope is going to save lives, he added.

'/>"/>
Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Green Tea, Mushroom Extract Combo Slows Sarcomas
2. Hormone Combo May Provide Reversible Male Birth Control Tool
3. LG Electronics Debuts Unique Allergen-Reducing Steam Washer/Dryer Combo
4. Combo Treatment Ups Survival When Cancer Spreads to Abdominal Lining
5. MRI/PET scanner combo
6. Treatment Combo for Pancreatic Cancer Has Limited Benefit
7. Raised Breast Cancer Risk Persists After Combo HRT Stopped
8. Combo Treatment Best for Melanoma, Advanced Ovarian Cancer
9. Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
10. Combo Therapy Shows Promise in Treating Brain Tumors
11. Combo Treatment Best for Elderly Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 1Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 2OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 1OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 2OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 3OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 4OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 5Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 1Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 2Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 3